Atrial Fibrillation: Inflammation in Disguise?

Scandinavian Journal of Immunology

Volumn 78, Issue 2, 2013, Pages 112-119

  Lappegard K T ^a,b   Hovland, A ^a,b   Pop, G A M ^c   Mollnes, T E ^a,b,d,e  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; C REACTIVE PROTEIN; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2;

ADIPOCYTE; ADIPOSE TISSUE; BLOOD TRANSFUSION; BLOOD VISCOSITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE COURSE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART SURGERY; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SECONDARY PREVENTION; SUPRAVENTRICULAR TACHYCARDIA; THROMBOSIS; VALVULAR HEART DISEASE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; HEART FAILURE; HUMANS; INFLAMMATION; STROKE; THROMBOEMBOLISM;

EID: 84879782075     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12061     Document Type: Review

References (113)

1. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
2. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
3. Cosedis Nielsen J, Johannessen A, Raatikainen P et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012;367:1587-95.
4. Jaïs P, Cauchemez B, Macle L et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118:2498-505.
5. Oral H, Pappone C, Chugh A et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006;354:934-41.
6. Pappone C, Augello G, Sala S et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006;48:2340-7.
7. Wazni O, Wilkoff B, Saliba W. Catheter ablation for atrial fibrillation. N Engl J Med 2011;365:2296-304.
8. Wilber DJ, Pappone C, Neuzil P et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303:333-40.
9. Kerr CR, Humphries KH, Talajic M et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005;149:489-96.
10. Klein WW. Arrhythmias in inflammatory heart disease. Wien Klin Wochenschr 1975;87:465.
11. Aviles RJ, Martin DO, Apperson-Hansen C et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
12. Loricchio ML, Cianfrocca C, Pasceri V et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007;99:1421-4.
13. Kaireviciute D, Lip GY, Balakrishnan B et al. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. J Thromb Haemost 2011;9:2345-52.
14. Hijazi Z, Oldgren J, Siegbahn A et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013 [Epub ahead of print].
15. Kijtawornrat A, Roche BM, Hamlin RL. A canine model of sustained atrial fibrillation induced by rapid atrial pacing and phenylephrine. Comp Med 2008;58:490-3.
16. Sridhar A, Nishijima Y, Terentyev D et al. Chronic heart failure and the substrate for atrial fibrillation. Cardiovasc Res 2009;84:227-36.
17. Verheule S, Wilson E, Everett T et al. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 2003;107:2615-22.
18. Watanabe I, Okumura Y, Kogawa R et al. Linear catheter ablation of the right atrium for rapid atrial pacing-induced sustained atrial fibrillation in dogs. Int Heart J 2012;53:375-82.
19. Abed HS, Samuel CS, Lau DH et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm 2013;10:90-100.
20. Letsas KP, Siklódy CH, Korantzopoulos P et al. The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation. Int J Cardiol 2013;164:94-8.
21. Alegret JM, Aragonès G, Elosua R et al. The relevance of the association between inflammation and atrial fibrillation. Eur J Clin Invest 2013;43:324-31.
22. Ichiki H, Orihara K, Hamasaki S et al. The role of infection in the development of non-valvular atrial fibrillation: up-regulation of Toll-like receptor 2 expression levels on monocytes. J Cardiol 2009;53:127-35.
23. Peña JM, Macfadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012;33:531-7.
24. Barassi A, Pezzilli R, Morselli-Labate AM et al. Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol 2012;28:537-41.
25. Mazza A, Bendini MG, Cristofori M et al. C-reactive protein and P-wave in hypertensive patients after conversion of atrial fibrillation. J Cardiovasc Med (Hagerstown) 2012 [Epub ahead of print].
26. Smit MD, Maass AH, De Jong AM et al. Role of inflammation in early atrial fibrillation recurrence. Europace 2012;14:810-7.
27. Kawamura M, Munetsugu Y, Kawasaki S et al. Type III procollagen-N-peptide as a predictor of persistent atrial fibrillation recurrence after cardioversion. Europace 2012;14:1719-25.
28. Marcus GM, Smith LM, Ordovas K et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 2010;7:149-54.
29. Li J, Song J, Jiang MH et al. Interleukin-6 promoter polymorphisms and susceptibility to atrial fibrillation in elderly Han Chinese patients with essential hypertension. J Interferon Cytokine Res 2012;32:542-7.
30. Dernellis J, Panaretou M. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am J Cardiol 2006;97:245-8.
31. Adamsson Eryd S, Smith JG, Melander O et al. Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study. Eur J Epidemiol 2011;26:449-55.
32. Marott SC, Benn M, Johansen JS et al. YKL-40 levels and atrial fibrillation in the general population. Int J Cardiol 2012 [Epub ahead of print].
33. De Gennaro L, Brunetti ND, Montrone D et al. Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur J Clin Invest 2012;42:371-5.
34. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L et al. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol 2012;157:397-402.
35. Richter B, Gwechenberger M, Socas A et al. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol 2012;101:217-25.
36. Hu YF, Yeh HI, Tsao HM et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ Arrhythm Electrophysiol 2012;5:334-40.
37. Henningsen KM, Therkelsen SK, Johansen JS et al. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 2009;11:1032-6.
38. Renkema GH, Boot RG, Au FL et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251:504-9.
39. Volck B, Price PA, Johansen JS et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998;110:351.
40. Liu L, Lee J, Fu G et al. Activation of peripheral blood CD3(+) T-lymphocytes in patients with atrial fibrillation. Int Heart J 2012;53:221-4.
41. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta 2012;413:3-14.
42. Reilly SM, Chiang SH, Decker SJ et al. An inhibitor of the protein kinases TBK1 and IKK-e{open} improves obesity-related metabolic dysfunctions in mice. Nat Med 2013;19:313-21.
43. Lin YK, Chen YC, Chen JH et al. Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation. Basic Res Cardiol 2012;107:293.
44. Nagashima K, Okumura Y, Watanabe I et al. Does location of epicardial adipose tissue correspond to endocardial high dominant frequency or complex fractionated atrial electrogram sites during atrial fibrillation? Circ Arrhythm Electrophysiol 2012;5:676-83.
45. Rienstra M, Sun JX, Lubitz SA et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J 2012;163:119-124.e1.
46. Gungor H, Ayik MF, Kirilmaz B et al. Serum resistin level: as a predictor of atrial fibrillation after coronary artery bypass graft surgery. Coron Artery Dis 2011;22:484-90.
47. Kourliouros A, Yin X, Didangelos A et al. Substrate modifications precede the development of atrial fibrillation after cardiac surgery: a proteomic study. Ann Thorac Surg 2011;92:104-10.
48. Ahlehoff O, Gislason GH, Jørgensen CH et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study. Eur Heart J 2012;33:2054-64.
49. Lindhardsen J, Ahlehoff O, Gislason H et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012;344:e1257.
50. Emilsson L, Smith JG, West J et al. Increased risk of atrial fibrillation in patients with coeliac disease: a nationwide cohort study. Eur Heart J 2011;32:2430-7.
51. Chiang CH, Huang CC, Chan WL et al. Herpes simplex virus infection and risk of atrial fibrillation: a nationwide study. Int J Cardiol 2013;164:201-4.
52. Garcia L, Verdejo HE, Kuzmicic J et al. Impaired cardiac autophagy in patients developing postoperative atrial fibrillation. J Thorac Cardiovasc Surg 2012;143:451-9.
53. Ling LH, Kistler PM, Ellims AH et al. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 2012;60:2402-8.
54. Frustaci A, Chimenti C, Bellocci F et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4.
55. Wang Y, Ripa RS, Johansen JS et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 2008;42:295-302.
56. Scridon A, Morel E, Nonin-Babary E et al. Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation. Europace 2012;14:948-53.
57. Marcus GM, Smith LM, Glidden DV et al. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm 2008;5:215-21.
58. Kaya MG, Akpek M, Elcik D et al. Relation of left atrial spontaneous echocardiographic contrast in patients with mitral stenosis to inflammatory markers. Am J Cardiol 2012;109:851-5.
59. Black IW, Chesterman CN, Hopkins AP et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993;21:451-7.
60. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004;148:462-6.
61. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007;38:1229-37.
62. Pop G, Duncker D, Gardien M et al. The clinical significance of whole blood viscosity in (cardio-)vascular medicine. Neth Heart J 2002;10:512-6.
63. Ami RB, Barshtein G, Zeltser D et al. Parameters of red blood cell aggregation as correlates of the inflammatory state. Am J Physiol Heart Circ Physiol 2001;280:H1982-8.
64. Chien S, Usami S, Dellenback RJ et al. Blood viscosity: influence of erythrocyte aggregation. Science 1967;157:829-31.
65. Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis: basic principles and applications. ICTH-Report-Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis. Thromb Haemost 1986;55:415-35.
66. Devereux RB, Drayer JI, Chien S et al. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 1984;54:592-5.
67. Banyai S, Banyai M, Falger J et al. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Atherosclerosis 2001;159:513-9.
68. Koch CG, Li L, Van Wagoner DR et al. Red cell transfusion is associated with an increased risk for postoperative atrial fibrillation. Ann Thorac Surg 2006;82:1747-56.
69. Dormandy J. The dangerous red cell. Clin Hemorheol 1984;4:115-32.
70. Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013;109:416-20.
71. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol 2013;35:254-61.
72. Erdem K, Ayhan S, Ozturk S et al. Usefulness of the mean platelet volume for predicting new-onset atrial fibrillation after isolated coronary artery bypass grafting. Platelets 2013 [Epub ahead of print].
73. Tekin G, Tekin YK, Sivri N, Yetkin E. Mean platelet volume in patients with nonvalvular atrial fibrillation. Blood Coagul Fibrinolysis 2013 [Epub ahead of print].
74. Ha SI, Choi DH, Ki YJ et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets 2011;22:408-14.
75. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 2008;51:1790-3.
76. Colkesen Y, Coskun I, Muderrisoglu H. The effect of aspirin on mean platelet volume in patients with paroxysmal atrial fibrillation. Platelets 2013;24:263-6.
77. Urner M, Herrmann IK, Buddeberg F et al. Effects of blood products on inflammatory response in endothelial cells in vitro. PLoS ONE 2012;7:e33403.
78. Dorneles Cde C, Bodanese LC, Guaragna JC et al. The impact of blood transfusion on morbidity and mortality after cardiac surgery. Rev Bras Cir Cardiovasc 2011;26:222-9.
79. Nishi H, Sakaguchi T, Miyagawa S et al. Atrial fibrillation occurring early after cardiovascular surgery: impact of the surgical procedure. Surg Today 2012 [Epub ahead of print].
80. Topal AE, Eren MN. Predictors of atrial fibrillation occurrence after coronary artery bypass graft surgery. Gen Thorac Cardiovasc Surg 2011;59:254-60.
81. Rotter M, Jaïs P, Vergnes MC et al. Decline in C-reactive protein after successful ablation of long-lasting persistent atrial fibrillation. J Am Coll Cardiol 2006;47:1231-3.
82. Young-Xu Y, Jabbour S, Goldberg R et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-83.
83. Hanna IR, Heeke B, Bush H et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006;3:881-6.
84. Fauchier L, Pierre B, de Labriolle A et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-35.
85. Hung CY, Lin CH, Loh el-W et al. CHADS(2) score, statin therapy, and risks of atrial fibrillation. Am J Med 2013;126:133-40.
86. Amar D, Zhang H, Heerdt PM et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005;128:3421-7.
87. Mariscalco G, Lorusso R, Klersy C et al. Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery. Ann Thorac Surg 2007;84:1158-64.
88. Baran Ç, Durdu S, Dalva K et al. Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial. Stem Cell Rev 2012;8:963-71.
89. Negi S, Shukrullah I, Veledar E et al. Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol 2011;22:414-9.
90. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92:1343-5.
91. Tveit A, Grundtvig M, Gundersen T et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004;93:780-2.
92. Rizos I, Tsiodras S, Rigopoulos AG et al. Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Cytokine 2007;40:157-64.
93. Imazio M, Brucato A, Ferrazzi P et al. Colchicine reduces postoperative atrial fibrillation: results of the colchicine for the prevention of the postpericardiotomy syndrome (COPPS) atrial fibrillation substudy. Circulation 2011;124:2290-5.
94. Calò L, Bianconi L, Colivicchi F et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723-8.
95. Carnes A, Chung K, Nakayama T et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001;89:e32-8.
96. Korantzopoulos P, Kolettis TM, Kountouris E et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005;102:321-6.
97. Kowey PR, Reiffel JA, Ellenbogen KA et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 2010;304:2363-72.
98. Ozaydin M, Erdoǧan D, Tayyar S et al. N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. Anadolu Kardiyol Derg 2011;11:305-9.
99. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9.
100. Chao TF, Leu HB, Huang CC et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 2012;156:199-202.
101. Rubens FD, Nathan H, Labow R et al. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann Thorac Surg 2005;79:655-65.
102. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1100-7.
103. Dieleman JM, van Paassen J, van Dijk D et al. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database Syst Rev 2011;CD005566.
104. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13:34-45.
105. Gao SP, Deng XT, Ge LJ et al. Is inflammation linked to thrombogenesis in atrial fibrillation? Int J Cardiol 2011;149:260-1.
106. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012;60:2263-70.
107. Ball J, Carrington MJ, Stewart S, on behalf of the SAFETY investigators. Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management? Heart 2013;99:542-7.
108. Bunch TJ, Weiss JP, Crandall BG et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 2010;7:433-7.
109. Kilander L, Andrén B, Nyman H et al. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 1998;29:1816-20.
110. Knecht S, Oelschläger C, Duning T et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125-32.
111. Kwok CS, Loke YK, Hale R et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 2011;76:914-22.
112. Tendolkar I, Enajat M, Zwiers MP et al. One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. Int J Geriatr Psychiatry 2012;27:49-58.
113. van Kuilenburg J, Lappegård KT, Sexton J et al. Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment. J Clin Lipidol 2011;5:273-80.